CytoSorb® Hemoadsorption as a Promising Tool to Handle COVID-19-Induced Cytokine Storm. (12th October 2021)

• Record Type: Journal Article
• Authors: Acevedo, Alice-Christin; Zoller, Michael; Scharf, Christina; Liebchen, Uwe; Irlbeck, Michael; Schroeder, Ines
• Other Names: Nin Nicolas Academic Editor.
• Is Part Of: Case reports in critical care. Volume 2021(2021)
• Publication Date: 2021-10-12
• Subjects: Critical care medicine -- Periodicals; Emergency medicine -- Periodicals; Medical emergencies -- Periodicals; 616.02805
• DOI: 10.1155/2021/9937499
• Languages: English
• ISSNs: 2090-6420

Abstract

Abstract : Accumulating evidence suggests that a patient subgroup with severe COVID-19 develops a cytokine release syndrome leading to capillary leakage and organ injury. Recent publications addressing therapy of cytokine storms recommended new extracorporeal therapies such as hemoadsorption. This case report describes a 59-year-old SARS-CoV-2-positive patient with severe ARDS. Due to severe hyperinflammation with concomitant hemodynamic instability and progressive renal failure, combination of continuous renal replacement and CytoSorb® hemoadsorption therapy was initiated. Treatment resulted immediately in a control of the hyperinflammatory response. Simultaneously, lung function continued to improve accompanied by profound hemodynamic stabilization. We report the successful utilization of CytoSorb® hemoadsorption in the treatment of a patient with SARS-CoV-2-induced cytokine storm syndrome.